3 registrations that name L-tyrosine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
RecruitingNCT07742982
Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser
Early phase 1
Aswan University
About 40 people
Started Jun 1, 2026
In plain words An early phase 1 study of L-tyrosine in people 18 to 60, run by Aswan University. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Focal Vitiligo.
What it tests, as registered
Tyrosine
Registered summary
Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots. It is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT06264544
Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism
No phase
S.LAB (SOLOWAYS)
About 150 people
Starts Jul 30, 2025 (estimated)
In plain words A study of L-tyrosine in people 18 to 85, run by S.LAB (SOLOWAYS). It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Thyrotoxicosis.
Confirmed presence of one or more specified gene polymorphism r25191G/A SEPP1
TPOAb levels > 300 IU/mL
The exclusion criteria are on the listing.
What it tests, as registered
zinc, selenium, and L-tyrosine in SEPP1; Placebo
Registered summary
This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
Not yet recruitingNCT07530185
Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers
No phase
Inonu University
About 18 people
Starts Sep 2026 (estimated)
In plain words A study of L-tyrosine in male participants 18 and older, run by Inonu University. It plans to enroll about 18 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older; healthy volunteers accepted. Conditions: Sports Performance.
Participants will complete six sessions, including one familiarization and baseline session followed by five experimental conditions: control (no supplementation), placebo, L-tyrosine, caffeine, and combined L-tyrosine plus caffeine. The experimental conditions will be performed in a randomized, counterbalanced crossover design with a washout period of at least 72 hours between sessions. The full summary is on the listing.